Get the Stockscreener App
2.73
2.25%
0.06
Bionexus Gene Lab Corp Stock (BGLC) Forecast
The Bionexus Gene Lab Corp (BGLC) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $1.216, representing a -55.46% decrease from the current price of $2.73. The highest analyst price target is $1.5174, and the lowest is $0.9145.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month BGLC Price Target
Average 2.3527
(-13.82% Downside)
Is Bionexus Gene Lab Corp (BGLC) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 48.97 | Neutral |
| STOCH(9,6) | 35.16 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | -0.1704 | Buy |
| ADX(14) | 24.69 | Neutral |
| William %R | -51.24 | Neutral |
| CCI(14) | 45.31 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.5236
Buy
|
2.593
Buy
|
| MA20 |
2.6433
Buy
|
2.6998
Buy
|
| MA50 |
3.1604
Sell
|
2.9978
Sell
|
| MA100 |
3.1827
Sell
|
3.2601
Sell
|
| MA200 |
3.6928
Sell
|
3.8509
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, BGLC could be considered a Moderate Sell, with 17 technical analysis indicators signaling 5 Buy signals, 7 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on BGLC, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 48.97 indicates that BGLC is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 35.16 indicates that BGLC is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that BGLC is oversold. This suggests that BGLC price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 24.69 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 45.31 indicates that BGLC is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term BGLC price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Bionexus Gene Lab Corp financial reports and earnings history, Bionexus Gene Lab Corp (BGLC) stock could reach $2.0843 by 2030, $5.0559 by 2040 and $8.0991 by 2050. See the projected annual prices until 2050 of the Bionexus Gene Lab Corp stock below:
- Bionexus Gene Lab Corp (BGLC) is expected to reach an average price of $3.6317 in 2035, with a high prediction of $4.0565 and a low estimate of $3.4332. This indicates an $33.03% rise from the last recorded price of $2.73.
- Bionexus Gene Lab Corp (BGLC) stock is projected to chart a bullish course in 2040, with an average price target of $4.3602, representing an $59.71% surge from its current level. The forecast ranges from a conservative $4.356 to a sky-high $5.0559.
- Our analysts predict Bionexus Gene Lab Corp (BGLC) to jump 126.08% by 2045, soaring from $5.7242 to an average price of $6.172, potentially reaching $8.7138. While $5.7242 is the low estimate, the potential upside is significant.
- Bionexus Gene Lab Corp (BGLC) stock is expected to climb by 2050, reaching an average of $7.8283, a $186.75% jump from its current level. However, a wide range of estimates exists, with high and low targets of $8.0991 and $7.6644, respectively, highlighting the market's uncertainty.
Bionexus Gene Lab Corp Stock (BGLC) Year by Year Forecast
Bionexus Gene Lab Corp Stock (BGLC) Price Forecast for 2025
Bionexus Gene Lab Corp Stock (BGLC) is expected to reach an average price of $2.2525 in 2025, with a high prediction of $3.7995 and a low estimate of $0.7054. This indicates an -17.49% fall from the last recorded price of $2.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $1.0475 | $0.9145 | $1.5174 | -61.63% |
| June, 2025 | $0.9326 | $0.9128 | $1.3328 | -65.84% |
| July, 2025 | $0.859 | $0.857 | $1.0143 | -68.53% |
| August, 2025 | $0.8427 | $0.8035 | $0.9958 | -69.13% |
| September, 2025 | $0.9855 | $0.8099 | $3.7995 | -63.90% |
| October, 2025 | $1.1394 | $1.0195 | $1.6232 | -58.26% |
| November, 2025 | $1.0406 | $1.0237 | $1.4437 | -61.88% |
| December, 2025 | $1.0005 | $0.9016 | $1.0945 | -63.35% |
Bionexus Gene Lab Corp Stock (BGLC) Price Forecast for 2026
The predicted value for Bionexus Gene Lab Corp (BGLC) in 2026 is set at an average of $2.5095. Estimates vary from a peak of $4.1067 to a trough of $0.9123, indicating an -8.08% surge from the present price of $2.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.9332 | $0.9187 | $1.0947 | -65.82% |
| February, 2026 | $1.2397 | $0.9123 | $3.9019 | -54.59% |
| March, 2026 | $1.2478 | $1.1918 | $1.729 | -54.29% |
| April, 2026 | $1.1831 | $1.134 | $1.5546 | -56.66% |
| May, 2026 | $1.0987 | $0.9998 | $1.1974 | -59.76% |
| June, 2026 | $1.0348 | $1.0203 | $1.1937 | -62.10% |
| July, 2026 | $1.4068 | $1.0147 | $4.0043 | -48.47% |
| August, 2026 | $1.2973 | $1.2432 | $1.475 | -52.48% |
| September, 2026 | $1.4555 | $1.2455 | $1.6655 | -46.68% |
| October, 2026 | $1.2227 | $1.0979 | $1.2926 | -55.21% |
| November, 2026 | $1.7467 | $1.1171 | $4.1067 | -36.02% |
| December, 2026 | $1.4621 | $1.2787 | $1.9406 | -46.44% |
Bionexus Gene Lab Corp Stock (BGLC) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Bionexus Gene Lab Corp (BGLC) is $2.7537, with a high forecast of $4.3114 and a low forecast of $1.196. This indicates an +0.87% increase from the last price of $2.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $1.4335 | $1.3524 | $1.5825 | -47.49% |
| February, 2027 | $1.5665 | $1.3565 | $1.7765 | -42.62% |
| March, 2027 | $1.2678 | $1.196 | $1.3916 | -53.56% |
| April, 2027 | $1.506 | $1.2194 | $4.209 | -44.84% |
| May, 2027 | $1.5687 | $1.3828 | $2.0464 | -42.54% |
| June, 2027 | $1.4872 | $1.4616 | $1.8874 | -45.52% |
| July, 2027 | $1.3856 | $1.3676 | $1.5732 | -49.25% |
| August, 2027 | $1.3677 | $1.2941 | $1.4906 | -49.90% |
| September, 2027 | $1.5059 | $1.3218 | $4.3114 | -44.84% |
| October, 2027 | $1.6926 | $1.5442 | $2.1522 | -38.00% |
| November, 2027 | $1.5981 | $1.5708 | $1.9983 | -41.46% |
| December, 2027 | $1.4425 | $1.4405 | $1.685 | -47.16% |
Bionexus Gene Lab Corp Stock (BGLC) Price Forecast for 2028
In 2028, Bionexus Gene Lab Corp (BGLC) is projected to reach an average price of $3.0054, with a high projection of $4.6186 and a low estimate of $1.3922. This indicates an +10.09% rise from the last price of $2.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.4467 | $1.3922 | $1.5895 | -47.01% |
| February, 2028 | $1.61 | $1.4242 | $4.4138 | -41.03% |
| March, 2028 | $1.7896 | $1.6491 | $2.258 | -34.45% |
| April, 2028 | $1.7113 | $1.68 | $2.1092 | -37.32% |
| May, 2028 | $1.5892 | $1.4903 | $1.7703 | -41.79% |
| June, 2028 | $1.5424 | $1.5274 | $1.6885 | -43.50% |
| July, 2028 | $1.8694 | $1.5266 | $4.5162 | -31.52% |
| August, 2028 | $1.8434 | $1.7893 | $2.3638 | -32.48% |
| September, 2028 | $1.8588 | $1.8002 | $2.2202 | -31.91% |
| October, 2028 | $1.6873 | $1.5884 | $1.8783 | -38.19% |
| November, 2028 | $2.2586 | $1.6281 | $4.6186 | -17.27% |
| December, 2028 | $2.0416 | $1.7992 | $2.4696 | -25.22% |
Bionexus Gene Lab Corp Stock (BGLC) Price Forecast for 2029
The 2029 price forecast for Bionexus Gene Lab Corp Stock (BGLC) is $3.2549 on average, with a high prediction of $4.8233 and a low estimate of $1.6865. This represents an +19.23% increase from the previous price of $2.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $1.9838 | $1.8985 | $2.1201 | -27.33% |
| February, 2029 | $2.1211 | $1.9111 | $2.3311 | -22.30% |
| March, 2029 | $1.8165 | $1.6865 | $1.8864 | -33.46% |
| April, 2029 | $2.3609 | $1.7287 | $4.7209 | -13.52% |
| May, 2029 | $2.102 | $1.9033 | $2.5754 | -23.00% |
| June, 2029 | $2.0939 | $2.0077 | $2.2276 | -23.30% |
| July, 2029 | $2.232 | $2.022 | $2.442 | -18.24% |
| August, 2029 | $1.8667 | $1.7846 | $1.9854 | -31.62% |
| September, 2029 | $2.1254 | $1.8294 | $4.8233 | -22.15% |
| October, 2029 | $2.2301 | $2.0073 | $2.6812 | -18.31% |
| November, 2029 | $2.1527 | $2.1169 | $2.5529 | -21.15% |
| December, 2029 | $1.964 | $1.946 | $2.2439 | -28.06% |
Bionexus Gene Lab Corp Stock (BGLC) Price Forecast for 2030
Bionexus Gene Lab Corp Stock (BGLC) is expected to reach an average price of $3.5066 in 2030, with a high forecast of $5.1305 and a low forecast of $1.8827. This signifies an +28.45% surge from the last price of $2.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.9501 | $1.8827 | $2.0843 | -28.57% |
| February, 2030 | $2.1304 | $1.934 | $4.9257 | -21.96% |
| March, 2030 | $2.3376 | $2.1738 | $2.787 | -14.37% |
| April, 2030 | $2.2636 | $2.2261 | $2.6638 | -17.08% |
| May, 2030 | $2.0261 | $2.0241 | $2.3557 | -25.79% |
| June, 2030 | $2.0507 | $1.9808 | $2.1833 | -24.88% |
| July, 2030 | $2.3941 | $2.0355 | $5.0281 | -12.30% |
| August, 2030 | $2.4398 | $2.3728 | $2.8928 | -10.63% |
| September, 2030 | $2.3819 | $2.3353 | $2.7748 | -12.75% |
| October, 2030 | $2.1778 | $2.0789 | $2.4461 | -20.23% |
| November, 2030 | $2.1515 | $2.1314 | $2.2823 | -21.19% |
| December, 2030 | $2.499 | $2.1409 | $5.1305 | -8.46% |
1.69%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):